Evidence map›Paper›PMID 30147300›Full record

ArticleDrug design, development and therapy2018

Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer.

Tivadar Bíró, Gabriella Horvát, Mária Budai-Szűcs, Erzsébet Csányi, Edit Urbán, Andrea Facskó, Piroska Szabó-Révész, Ildikó Csóka, Zoltán Aigner

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Treatment of Acute Ulcerative Colitis with Zinc Hyaluronate in Mice.Journal of microbiology and biotechnology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tivadar BíróInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary, aigner@pharm.u-szeged.hu.
Gabriella HorvátInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary, aigner@pharm.u-szeged.hu.
Mária Budai-SzűcsInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary, aigner@pharm.u-szeged.hu.
Erzsébet CsányiInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary, aigner@pharm.u-szeged.hu.
Edit UrbánDepartment of Clinical Microbiology, Faculty of Medicine, University of Szeged, Szeged, Hungary.
Andrea FacskóOphthalmology Department, Faculty of Medicine, University of Szeged, Szeged, Hungary.
Piroska Szabó-RévészInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary, aigner@pharm.u-szeged.hu.
Ildikó CsókaInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary, aigner@pharm.u-szeged.hu.
Zoltán AignerInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary, aigner@pharm.u-szeged.hu.
University of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe formulation of topical ophthalmic products with appropriate therapeutic effect and patient compliance is a major challenge. To increase the efficiency of the ocular delivery of the drug, the enhancement of water solubility and the contact time of the drug on the surface of the cornea are necessary. In this work, prednisolone (PR)-containing eye drops were formulated with antimicrobial, mucoadhesive biopolymer and PR-cyclodextrin inclusion complex. This approach can be used for the development of innovative ophthalmic formulations. MATERIALS AND

methodsAfter adjusting the optimal physiological parameters, the amount of the required cyclodextrin for the highest penetration of PR was determined by dialysis membrane diffusion study. The viscosity, surface tension and mucoadhesion of the eye drops were measured. The microbiological effectiveness of zinc-hyaluronate (ZnHA) was investigated by a standard method of the European Pharmacopoeia.

resultsIn this case, no significant difference of surface tension was measured in products with different amounts of cyclodextrin. According to the results of the tensile test, ZnHA as a mucoadhesive biopolymer improves the mucoadhesion of ophthalmic products. The antimicrobial stability of formulations preserved by ZnHA meets requirement B of the European Pharmacopoeia.

conclusionIt can be stated that the innovative PR-containing compositions are suitable for producing mucoadhesive, properly preserved aqueous ophthalmic solutions with increased bioavailability attributes.

Indexed as

Drug CarriersAdhesivenessAdministration, OphthalmicAnti-Infective AgentsCandida albicansDrug CompoundingDrug Stabilitygamma-CyclodextrinsGlucocorticoidsHyaluronic AcidOphthalmic SolutionsOrganometallic CompoundsPrednisolonePseudomonas aeruginosaSolubilityStaphylococcus aureusAnti-Infective AgentsDrug Carriersgamma-CyclodextrinsGlucocorticoidsHyaluronic Acidhydroxypropyl-gamma-cyclodextrinOphthalmic SolutionsOrganometallic CompoundsPrednisolonezinc hyaluronate complexmembrane diffusionmicrobiological stabilityocular drug deliverypharmaceutical formulationzinc-hyaluronate

Identifiers

PMID30147300
PMCPMC6101011
OpenAlexW2887307769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.